Department of Radiation Oncology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Radiotherapy Department of Nasopharyngeal Carcinoma, Cancer Center, First People's Hospital of Foshan Affiliated to Sun Yat-sen University, Foshan, China.
Radiother Oncol. 2021 Feb;155:219-225. doi: 10.1016/j.radonc.2020.11.011. Epub 2020 Nov 18.
To assess the impact of tumor necrosis on treatment sensitivity and long-term survival in patients with nasopharyngeal carcinoma (NPC) treated using intensity-modulated radiation therapy (IMRT).
In total, 757 patients with non-metastatic, histologically confirmed NPC were retrospectively examined. All patients were treated using IMRT; 93.7% patients with stage T3-T4/N1-N3 disease also received cisplatin-based chemotherapy.
The incidence rates of tumor necrosis in primary tumor, retropharyngeal lymph nodes, neck lymph nodes, and total tumor were 2%, 17.7%, 21.5%, and 31.4%. Overall, 40.8% patients with necrosis of the total tumor achieved complete response (CR) and 54.7% patients without tumor necrosis achieved CR at the end of treatment (χ = 12.728, P < 0.001). The estimated 7-year overall survival (OS), failure-free survival (FFS), distant metastasis-free survival (DMFS), and loco-regional relapse-free survival (LRRFS) for patients with tumor necrosis and without tumor necrosis of the total tumor were 68.5% vs. 88.4%, 70.5% vs. 88.1%, 77.6% vs. 90.6%, and 85.9% vs. 91.3%, respectively (all P < 0.001). Multivariate analyses indicated that necrosis of the total tumor was an independent predictor of OS, FFS, DMFS, and LRRFS. The impact of lymph node necrosis on long-term survival was similar to that of necrosis of the total tumor. ROC curves verified that inclusion of lymph node necrosis improved the predictive value of the current N classification criteria (P = 0.006).
Tumor necrosis served as a predictor of treatment sensitivity and poor prognosis for patients with NPC. Lymph node necrosis significantly improved the prognostic value of the current N classification criteria for NPC.
评估肿瘤坏死对接受调强放疗(IMRT)治疗的鼻咽癌(NPC)患者治疗敏感性和长期生存的影响。
共回顾性分析了 757 例非转移性、组织学证实的 NPC 患者。所有患者均接受 IMRT 治疗;93.7%的 T3-T4/N1-N3 期患者还接受顺铂为基础的化疗。
原发肿瘤、咽后淋巴结、颈部淋巴结和总肿瘤的肿瘤坏死发生率分别为 2%、17.7%、21.5%和 31.4%。总的来说,40.8%的总肿瘤坏死患者达到完全缓解(CR),54.7%的无肿瘤坏死患者在治疗结束时达到 CR(χ²=12.728,P<0.001)。有肿瘤坏死和无总肿瘤坏死的患者 7 年总生存率(OS)、无失败生存率(FFS)、无远处转移生存率(DMFS)和无局部区域复发生存率(LRRFS)分别为 68.5%比 88.4%、70.5%比 88.1%、77.6%比 90.6%和 85.9%比 91.3%(均 P<0.001)。多因素分析表明,总肿瘤坏死是 OS、FFS、DMFS 和 LRRFS 的独立预测因素。淋巴结坏死对长期生存的影响与总肿瘤坏死相似。ROC 曲线验证了包含淋巴结坏死可提高当前 N 分类标准的预测价值(P=0.006)。
肿瘤坏死是 NPC 患者治疗敏感性和预后不良的预测因素。淋巴结坏死显著提高了当前 NPC N 分类标准的预后价值。